De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients

doi:10.3748/wjg.v17.i43.4804

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3193)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

320

HTML

2482

Figures (1-1)

209

Tables (1-3)

182

Sum=3193

Nov 21, 2011 (publication date) through Aug 27, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Nov 21, 2011; 17(43): 4804-4809
Published online Nov 21, 2011. doi: 10.3748/wjg.v17.i43.4804

Table 1 Characteristics of patients at baseline, median (min-max)

Characteristic	De novo combination group (n = 10)	Add-on combination group (n = 20)	P value
Age (yr)	45.6 ± 8.2	45.2 ± 8.2	0.89
Gender (males,%)	6 (60%)	11 (55%)	1
Height (m)	1.7 ± 0.7	1.7 ± 0.9	0.58
Weight (kg)	68.9 ± 9.7	67.3 ± 10.5	0.69
BMI (kg/m²)	23.8 ± 1.8	23.7 ± 1.6	0.88
HBV DNA levels (log₁₀, copies/mL)	6.23 ± 0.91	6.43 ± 0.95	0.58
Serum ALT (IU/L)	124 (82-156)	283 (187-321)	0
Serum TBIL (μmol/L)	49.5 (23-72)	73.5 (49.0-99.6)	0.001
Serum ALB (g/L)	29.75 (25.40-34.00)	26.65 (23.00-32.00)	0.021
Child-Pugh score	11 (9-13)	11 (9-13)	0.809
Red blood cell counts (× 10¹²/L)	3.6 (3.0-4.5)	3.3 (1.9-5.0)	0.234
HB (g/L)	106 (90-120)	97 (75-115)	0.059
White blood cell counts (× 10⁹/L)	3.85 (2.70-6.80)	3.75 (1.90-6.00)	0.657
Blood PLT count (× 10⁹/L)	96 (76-150)	96 (50-112)	0.657
Serum BUN (mmol/L)	6.05 (3.70-8.10)	4.35 (1.90-8.50)	0.139
Serum Cr (μmol/L)	99.5 (77.0-145.0)	77.0 (40.0-156.0)	0.024

BMI: Body mass index; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; TBIL: Total bilirubin; ALB: Albumin; HB: Hemoglobin; PLT: Platelet; BUN: Blood urine nitrogen; Cr: Creatinine.

Table 2 Biochemical responses of the patients, median (min-max)

	De novo combination group (n = 10)					Add-on combination group (n = 20)
	2 wk before combination treatment	4 wk after combination treatment	12 wk after combination treatment	24 wk aftercombinationtreatment	48 wk after combination treatment	2 wk before combination treatment	4 wk after combination treatment	12 wk after combination treatment	24 wk after combination treatment	48 wk after combination treatment
Child-Pugh score	11 (9-13)	10 (8-12)	10 (8-12)	9 (7-11)^c	7 (6-9)^c^a	11 (9-13)	10 (9-12)	10 (9-12)	10 (7-11)^c	9 (7-10)^c
Serum ALT (IU/L)	124 (82-156)^a	111 (80-141)^a	109 (69-125)^a	89 (59-112)^c^a	49 (28-67)^c^a	283 (187-321)	251 (171-302)^c	218 (146-277)^c	173 (105-239)^c	105 (65-186)^c
Serum TBIL (μmol/L)	49.5 (23-72)^a	47.3 (25.0-70.1)^a	41.3 (25.5-63.0)^a	37.8 (22.5-57.4)^c^a	31.0 (22.0-41.0)^c^a	73.5 (49.0-99.6)	68.3 (44.5-88.7)	63.5 (35.8-79.0)^c	56.7 (32.0-72.3)^c	41.2(29.0-58.1)^c
Serum ALB (g/L)	29.75(25.40-34.00)^a	30.15(27.20-34.10)^a	30.55(27.60-33.00)^a	32.80(29.00-35.00)^c^a	34.00(30.00-37.00)^c^a	26.65(23.00-32.00)	28.20(25.60-32.90)	27.85(25.00-31.90)	28.75(25.50-33.00)^c	30.5(28.0-34.8)^c

^aP < 0.05 vs add-on combination group;

^cP < 0.05 vs 2 wk before combination treatment in the same group. ALT: Alanine aminotransferase; TBIL: Total bilirubin; ALB: Albumin.

Table 3 Blood cell counts and renal function of the patients, median (min-max)

	De novo combination group (n = 10)					Add-on combination group (n = 20)
	2 wk before combination treatment	4 wk after combination treatment	12 wk after combination treatment	24 wk after combination treatment	48 wk after combination treatment	2 wk before combination treatment	4 wk after combination treatment	12 wk after combination treatment	24 wk after combination treatment	48 wk after combination treatment
Red blood cell counts (× 10¹²/L)	3.6 (3.0-4.5)	3.4 (3.0-4.3)	3.5 (2.9-4.1)	3.6 (3.1-4.0)^a	3.8 (3.0-5.1)^a	3.3 (1.9-5.0)	3.2 (2.3-4.1)	3.1 (2.5-4.0)	3.1 (2.5-3.9)	3.1 (2.7-3.4)^c
HB (g/L)	106 (90-120)	104 (92-113)^a	102 (99-115)	107 (94-114)^a	105 (85-121)^a	97 (75-115)	95 (80-114)	95 (85-111)	99 (88-112)	97 (84-105)
White blood cell counts (× 10⁹/L)	3.85 (2.70-6.80)	3.90 (2.90-5.70)	3.80 (3.00-5.20)	3.95 (3.20-4.70)	4.00 (3.00-4.50)	3.75 (1.90-6.00)	3.75 (2.50-5.60)	3.70 (2.90-5.00)	3.75 (2.90-4.70)	3.85 (3.00-5.10)
Blood PLT counts (× 10⁹/L)	96 (76-150)	90 (72-100)	94 (70-116)	95 (68-108)	98 (72-103)	96 (50-112)	94 (63-111)	92 (76-110)	90 (69-107)	93 (73-112)
Serum BUN (mmol/L)	6.05 (3.70-8.10)	5.90 (3.00-7.40)	5.65 (3.60-7.10)	5.50 (2.50-6.80)	5.45 (3.30-7.00)	4.35 (1.90-8.50)	5.25 (2.20-8.70)	5.00 (2.20-8.00)	5.00 (2.90-7.50)	4.95 (2.30-7.10)
Serum Cr (μmol/L)	99.5 (77.0-145.0)^a	96.5 (76.0-141.0)	96.0 (69.0-112.0)	78.0 (56.0-99.0)^c	78.5 (61.0-107.0)^c	77.0 (40.0-156.0)	95.5 (61.0-124.0)	86.0 (68.0-131.0)	73.5 (42.0-132.0)	79.0 (41.0-132.0)

^aP < 0.05 vs add-on combination group;^cP < 0.05 vs 2 wk before combination treatment in the same group. HB: Hemoglobin; PLT: Platelet; BUN: Blood urine nitrogen; Cr: Creatinine.

Citation: Fan XH, Geng JZ, Wang LF, Zheng YY, Lu HY, Li J, Xu XY. De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients. World J Gastroenterol 2011; 17(43): 4804-4809
URL: https://www.wjgnet.com/1007-9327/full/v17/i43/4804.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i43.4804